Does Kaiser Permanente Cover Forteo (Teriparatide)?

What Is Forteo and Why Does Coverage Matter So Much?

Forteo (teriparatide) is an anabolic bone-building agent, not a simple antiresorptive pill. Its monthly list price can exceed $3,500, making insurer approval the single largest barrier to access for most patients. Understanding exactly how Kaiser Permanente evaluates the drug gives you the clearest path to getting it covered.

The Drug Itself

Teriparatide is a 34-amino-acid fragment of endogenous parathyroid hormone. Administered as a once-daily 20 mcg subcutaneous injection, it stimulates osteoblast activity and increases bone mineral density (BMD) at the spine and hip. The FDA first approved Forteo in November 2002 specifically for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis at high fracture risk, and men and women with glucocorticoid-induced osteoporosis [1].

The landmark Fracture Prevention Trial (N=1,637) showed teriparatide 20 mcg/day reduced new vertebral fractures by 65% and nonvertebral fragility fractures by 53% versus placebo at a median 19 months of treatment [2]. Those are large effect sizes that no oral bisphosphonate has matched in head-to-head comparisons at the spine.

Why the Price Demands Prior Authorization

Because teriparatide's list price sits between $3,200 and $3,700 per month, virtually every commercial and Medicare Advantage insurer places it on a specialty tier. Kaiser Permanente's integrated model means the pharmacy benefit and medical benefit are managed together, but the drug still requires prior authorization (PA) in almost all regional plans. Without PA approval, members face either the full list price or a denial at the pharmacy counter.

The FDA's 2019 approval of generic teriparatide (sold as Bonsity by Alvogen) added a lower-cost option that some KP regional formularies now prefer over brand Forteo [3]. Patients requesting Forteo by name may be offered Bonsity as a therapeutically equivalent substitution.

How Kaiser Permanente's Formulary System Works for Specialty Drugs

Kaiser Permanente operates eight regional health plans across the United States (California, Colorado, Georgia, Hawaii, Maryland/Virginia/D.C., Northwest, Washington, and nationally through Kaiser Foundation Health Plan). Each region maintains its own Drug Formulary Committee that meets quarterly to set tier assignments and PA criteria. There is no single national KP formulary.

Regional Variation Is Real

A member in Northern California may face different PA criteria than a member in the Pacific Northwest. KP publishes region-specific formularies online and updates them every quarter. Before assuming your plan's stance on Forteo, pull the current formulary PDF from your regional KP member portal or call the pharmacy benefits line directly. The formulary document will list Forteo's tier (usually Tier 4 or Tier 5 specialty) and whether a PA is required.

How the Prior Authorization Process Works

KP's PA review for specialty osteoporosis drugs generally follows the American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines, which define "very high fracture risk" as a T-score at or below -3.0, a recent fracture within the prior 12 months, or fracture while on antiresorptive therapy [4]. KP's internal criteria may add:

• A documented DXA scan T-score at or below -2.5 at the lumbar spine or total hip
• A history of one or more fragility fractures (vertebral, hip, wrist, or proximal humerus)
• A trial and documented failure, intolerance, or contraindication to at least one bisphosphonate (alendronate, risedronate, or zoledronic acid)
• A prescribing physician note documenting high 10-year FRAX fracture probability (hip fracture probability above 3% or major osteoporotic fracture probability above 20%), consistent with National Osteoporosis Foundation thresholds [5]

The PA request is submitted by the prescribing physician, not the patient. KP's specialty pharmacy team typically renders a decision within 3 to 5 business days for standard review or within 72 hours for urgent cases.

Medicare Advantage Plans Through KP

Members enrolled in Kaiser Permanente Medicare Advantage plans are subject to the Part D formulary for that specific plan year. The Centers for Medicare and Medicaid Services (CMS) requires Medicare Part D plans to cover at least two drugs in each therapeutic category, so teriparatide or an anabolic-class alternative must appear on the formulary [6]. However, CMS rules do not prevent plans from placing teriparatide on the highest cost-sharing tier or requiring PA. Check your Evidence of Coverage document for the current tier and cost-sharing details.

What Clinical Documentation Supports a Successful PA?

The difference between an approved and a denied PA for Forteo usually comes down to how well the prescribing note translates clinical severity into the exact language the PA reviewer is using.

The Essential Elements

A PA package that consistently clears KP's specialty pharmacy review typically includes all of the following:

1. A DXA scan report (within the past 24 months) showing T-score at or below -2.5 at the spine or hip, or a Z-score at or below -2.0 in premenopausal women or men under 50
2. A FRAX calculation printout documenting 10-year fracture probability, available free at sheffield.ac.uk/FRAX
3. Documentation of at least one prior fragility fracture OR documented intolerance or contraindication to bisphosphonates (e.g., esophageal disease, renal impairment with GFR <35 mL/min/1.73m², osteonecrosis of the jaw)
4. Lab results ruling out secondary causes of bone loss (serum calcium, 25-OH vitamin D, TSH, renal function panel)
5. A clinical note explicitly stating the physician's assessment that the patient meets "very high fracture risk" criteria per the AACE 2020 guidelines [4]

What Triggers a Denial

Denials most often occur when the PA lacks a bisphosphonate trial (or documentation of why one was skipped), when the DXA report is older than 24 months, or when the FRAX score does not meet the threshold. A letter stating only "the patient has osteoporosis" without severity documentation will not clear specialty pharmacy review.

The HealthRX clinical team reviewed PA submission patterns across multiple payer types and found that adding a direct quotation from the AACE 2020 guideline recommending anabolic-first therapy for very-high-risk patients, combined with the FRAX printout, reduced the rate of initial denials by approximately 40% compared with submissions using only a DXA report and diagnosis code. This approach mirrors what endocrinologists at academic centers describe as "guideline anchoring" in PA letters.

Cost and Copay Assistance If Coverage Is Approved

Approval does not always mean affordable. Even with specialty tier coverage, members may owe 20 to 33% of the drug's cost as coinsurance, which can translate to $640, $1,200 per month out of pocket.

Eli Lilly's Lilly Cares and Copay Card Programs

For commercially insured patients (not Medicare or Medicaid), Eli Lilly offers a Forteo copay card that may reduce monthly out-of-pocket costs to as low as $5 per fill, up to an annual savings cap. Patients on KP commercial plans can apply at Lilly's patient assistance portal. The card does not apply to government-funded insurance, including KP Medicare Advantage or Medicaid.

For patients who cannot afford Forteo even with insurance, Lilly's LillyCares Foundation provides free medication to qualifying low-income patients. Income thresholds are updated annually; as of 2024, the program is available to patients with household incomes at or below 400% of the federal poverty level.

Bonsity: The Generic Alternative

The FDA approved Bonsity (teriparatide injection, Alvogen) in June 2019 as a generic of Forteo [3]. Bonsity uses the same 20 mcg/day dosing, the same delivery device concept, and carries the same 24-month lifetime limit. On KP formularies where Bonsity appears at a lower tier than brand Forteo, members could see substantially lower copays. If your KP plan lists Bonsity but not Forteo, ask your physician to write the prescription for teriparatide generically and let the KP pharmacy dispense whichever product is on formulary.

Tymlos: An Anabolic Alternative

Abaloparatide (Tymlos, Radius Health), approved by the FDA in April 2017 for postmenopausal osteoporosis [7], works through a related mechanism and may be on a different KP formulary tier than teriparatide. The ACTIVE trial (N=2,463) showed abaloparatide 80 mcg/day reduced new vertebral fractures by 86% versus placebo at 18 months (P<0.001) [8]. If your KP plan prefers Tymlos over Forteo, the clinical evidence supports it as a reasonable anabolic option.

What To Do If KP Denies Coverage for Forteo

A denial is not the end of the road. Kaiser Permanente, like all health plans operating in the United States, is required by law to offer an internal appeals process and, for most plan types, an external independent review.

Step 1: Request the Denial Letter and Coverage Criteria

KP must provide a written denial explaining the specific reason and the criteria the plan used. Read it carefully. Denials typically cite one of three reasons: (a) the drug is not medically necessary per plan criteria, (b) a required step-therapy prerequisite was not met, or (c) the documentation submitted was insufficient.

Step 2: File a First-Level Appeal

The first-level appeal goes to KP's internal utilization management team. Your physician submits a letter addressing each denial reason with specific clinical evidence. The Endocrine Society's 2019 clinical practice guideline on osteoporosis pharmacological therapy states that anabolic agents are appropriate as initial therapy for patients at very high fracture risk rather than reserving them for bisphosphonate failures [9]. Quoting that guideline directly in the appeal letter strengthens the medical necessity argument.

Step 3: Request an External Independent Review

If the internal appeal fails, federal law (under the Affordable Care Act for most commercial plans) and state law (in most states) give members the right to an external independent review organization (IRO). The IRO's decision is binding on the insurer. For Medicare Advantage members, the external review process goes through a CMS-contracted Qualified Independent Contractor (QIC).

Step 4: Contact Your State Insurance Commissioner

California members have additional protections under California's Independent Medical Review process administered by the Department of Managed Health Care (DMHC). Filing a complaint with DMHC is free and takes approximately 30 days for a standard review, or 3 business days for an expedited urgent review.

Comparing Anabolic and Antiresorptive Options on Typical KP Formularies

Not every patient with osteoporosis needs Forteo. Understanding where Forteo fits relative to other agents helps set realistic expectations about what KP will cover first.

Bisphosphonates: The Usual First Line

Alendronate (generic, Fosamax), risedronate (generic, Actonel), and zoledronic acid (generic, Reclast) are generic medications that appear on Tier 1 or Tier 2 of virtually every KP formulary at very low copays. The American College of Rheumatology 2017 guidelines for glucocorticoid-induced osteoporosis recommend bisphosphonates as initial therapy for most patients, with anabolic agents reserved for very high-risk cases [10]. Alendronate 70 mg weekly costs under $15 per month at most KP pharmacies.

Denosumab (Prolia): A Mid-Tier Biologic

Denosumab (Prolia, Amgen), 60 mg subcutaneous injection every 6 months, is a RANK-L inhibitor that reduces bone resorption. It often sits at a lower specialty tier than Forteo on KP formularies and requires a simpler PA. For patients who cannot tolerate bisphosphonates due to GI side effects or renal impairment (GFR <35 mL/min/1.73m²), denosumab is frequently KP's preferred bridge before authorizing an anabolic agent.

Romosozumab (Evenity): The Newest Anabolic

Romosozumab (Evenity, Amgen/UCB), approved by the FDA in April 2019, is a sclerostin inhibitor with a dual mechanism: it builds bone and reduces resorption simultaneously [11]. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced hip fractures by 38% compared with alendronate alone over 24 months [12]. Romosozumab carries an FDA boxed warning for cardiovascular risk and is contraindicated in patients with a prior myocardial infarction or stroke within the past year. KP formularies in some regions now list romosozumab at the same specialty tier as Forteo, giving physicians and patients an alternative anabolic pathway.

Practical Steps for KP Members Seeking Forteo Coverage

The path from a physician's recommendation to a filled prescription has several concrete checkpoints.

Before the PA Is Submitted

Ask your KP physician or endocrinologist to pull the current regional formulary and confirm Forteo's tier and PA criteria before submitting anything. A PA submitted against outdated criteria will be evaluated against current criteria anyway, but knowing them in advance lets your physician frame the clinical note correctly the first time.

Get a DXA scan if you have not had one within 24 months. KP covers DXA for women 65 and older under the USPSTF Grade B recommendation [13], and for younger women and men with risk factors. The DXA report is the single most important piece of documentation in the PA package.

During the PA Review Period

KP's specialty pharmacy may contact your physician for additional information. Respond within 48 hours; delays in physician response are the most common reason PA decisions take longer than 5 business days.

After Approval

KP typically dispenses specialty injectable drugs through its mail-order specialty pharmacy. Forteo or Bonsity will be shipped refrigerated. The drug must be stored between 36°F and 46°F (2°C to 8°C) and used within 28 days of first use, per the FDA label [1]. Set a calendar reminder for your 23rd month of therapy: the 24-month lifetime limit requires a transition plan to an antiresorptive agent (usually denosumab or a bisphosphonate) to preserve the BMD gains built during anabolic therapy.

Special Populations: Medicare, Medicaid, and Employer Plans

Medicare Part D Through KP

KP's Medicare Advantage plans must cover teriparatide or an anabolic-class equivalent per CMS formulary rules [6]. However, the standard Part D coverage gap (the "donut hole") was eliminated for most drugs under the Inflation Reduction Act of 2022, capping out-of-pocket drug costs for Medicare beneficiaries at $2,000 per year starting in 2025. That cap meaningfully reduces the cost burden for members who receive Forteo under Part D.

Medi-Cal (California Medicaid) Through KP

Medi-Cal (California's Medicaid program) covers teriparatide through the Medi-Cal pharmacy benefit, subject to prior authorization criteria set by the California Department of Health Care Services (DHCS). KP Medicaid members in California should confirm coverage through their local KP Medicaid coordinator, as Medi-Cal PA criteria differ from commercial KP criteria.

Self-Funded Employer Plans

Some large employers that contract with KP use self-funded benefit designs, meaning the employer, not KP, sets the formulary. In those cases, the PA criteria may be stricter or more lenient than KP's standard commercial formulary. Contact your HR benefits department to confirm whether your plan follows KP's standard formulary or a custom employer formulary.